# Tirzepatide 5 mg vs Semaglutide 1.7 mg Over Three Months: Weight and Appetite

See what a three-month observational study of tirzepatide 5 mg and semaglutide 1.7 mg found about weight and reported appetite.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/tirzepatide-vs-semaglutide-mismatched-doses
Updated: 2026-11-15
Published: 2026-09-16

[← Research](https://buythisglp.com/research)

Evidence

# Tirzepatide 5 mg vs Semaglutide 1.7 mg Over Three Months: Weight and Appetite

A three-month observational study in 183 adults examined weight and appetite with weekly tirzepatide 5 mg and semaglutide 1.7 mg.

Editorial profile: [Carla Medina](https://buythisglp.com/authors/carla-medina)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20264 min readUpdated November 2026

Average weight loss at three months · Semaglutide 1.7 mg · 8.15 kg · Tirzepatide 5 mg · 11.02 kg

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

In a three-month study at one clinic in China, adults receiving tirzepatide lost more weight on average than those receiving semaglutide. The comparison included 183 adults with obesity and without diabetes. Physicians chose each person’s treatment, and researchers compared the groups retrospectively [\[1\]](https://buythisglp.com/research/tirzepatide-vs-semaglutide-mismatched-doses#ref-1).

## Key takeaways

-   The study compared weekly regimens of semaglutide 1.7 mg and tirzepatide 5 mg.
-   Average weight loss was 8.15 kg with semaglutide and 11.02 kg with tirzepatide.
-   The unadjusted difference was 2.87 kg (95% confidence interval 1.32–4.41 kg).
-   The study did not detect a clear difference in reported appetite or food cravings.

## What the doses represent

The study used weekly semaglutide 1.7 mg (86 participants) and weekly tirzepatide 5 mg (97 participants) [\[1\]](https://buythisglp.com/research/tirzepatide-vs-semaglutide-mismatched-doses#ref-1). In the U.S. weight-management labels, 1.7 mg weekly is a Wegovy maintenance option, with 2.4 mg recommended and Wegovy HD available for some adults who need more weight reduction. The Zepbound label lists 5 mg, 10 mg and 15 mg as weight-management maintenance options [\[2\]](https://buythisglp.com/research/tirzepatide-vs-semaglutide-mismatched-doses#ref-2) [\[3\]](https://buythisglp.com/research/tirzepatide-vs-semaglutide-mismatched-doses#ref-3).

Our guide to [doses reached in routine care](https://buythisglp.com/research/what-dose-do-most-people-actually-reach) explains why an available dose can differ from the one people take. This study’s results apply to the two regimens it compared over three months. It cannot establish a dose conversion between the medications.

## Weight, appetite and side effects

Average weight loss was 11.02 kg with tirzepatide and 8.15 kg with semaglutide, an unadjusted difference of 2.87 kg (95% confidence interval 1.32–4.41 kg). The authors also estimated that the share reaching the study’s 10% weight-loss threshold was 21.50 percentage points higher with tirzepatide (95% confidence interval 7.45–35.55 points)[\[1\]](https://buythisglp.com/research/tirzepatide-vs-semaglutide-mismatched-doses#ref-1).

The two questionnaires tracked control of eating and appetite. The authors did not report a clear difference between groups in cravings and appetite scores. They also did not detect statistically significant differences in gastrointestinal or psychiatric side effects over three months [\[1\]](https://buythisglp.com/research/tirzepatide-vs-semaglutide-mismatched-doses#ref-1).

What the study could establish

Treatment choice may have reflected differences between patients that the study did not account for. Its size and duration also limit what the questionnaire and side-effect results can tell us about equivalence or long-term safety [\[1\]](https://buythisglp.com/research/tirzepatide-vs-semaglutide-mismatched-doses#ref-1).

## How dose affects a price comparison

The [dose pricing tool](https://buythisglp.com/tools/flat-or-rising) helps compare whether quoted prices change across dose levels. Use the price for the dose you are comparing. This study reports weight and appetite outcomes and does not estimate what either regimen costs.

## Frequently asked

Which group lost more weight?

At three months, the tirzepatide group lost 11.02 kg on average and the semaglutide group lost 8.15 kg. The unadjusted difference was 2.87 kg (95% confidence interval 1.32–4.41 kg).

Did the study establish equivalent doses?

The study compared two specific weekly regimens: tirzepatide 5 mg and semaglutide 1.7 mg. It could not establish a conversion between these drugs.

Did either group report more appetite changes?

The study did not detect a clear between-group difference in the food-craving or appetite questionnaire scores. It could not establish that the drugs have equivalent effects on appetite.

## Sources

1.  \[1\] Yao Z, et al. (2026). Comparative Efficacy of Semaglutide and Tirzepatide in Chinese Adults with Obesity without Diabetes: A Real-World Observational Study Diabetes, Metabolic Syndrome and Obesity. [PMID 42610030](https://www.tandfonline.com/doi/full/10.2147/DMSO.S607678)
2.  \[2\] Novo Nordisk (2026). Wegovy prescribing information, section 2.2 DailyMed, U.S. National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b)
3.  \[3\] Eli Lilly (2026). Zepbound prescribing information, recommended maintenance dosage DailyMed, U.S. National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b)

## Where to get it

### Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

[Open the price desk →](https://buythisglp.com/)

## More in Evidence

-   [
    
    50,678 adults with a BMI of 30 or more · Prescribed · 8.0% · Filled · 4.4% · Outlined bar runs to 10%. Medicaid had lower odds of both.
    
    ### Does Medicaid Cover Weight Loss Drugs? It Depends on Your State
    
    ](https://buythisglp.com/research/does-medicaid-cover-weight-loss-drugs)
-   [
    
    What the claim rests on · Sleep study · AHI 15 or more · Obesity · BMI 30 or more · Prescription · for sleep apnea · Part D claim · plan review · Trial thresholds shown. Your plan sets its approval requirements.
    
    ### Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key
    
    ](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea)
-   [
    
    Illustrative decline with a one-week half-life · Ozempic window: up to 5 days late · 100% · day 0 · 82% · day 2 · 67% · day 4 · 61% · day 5 · 50% · day 7 · A calculation from the label half-life, not a blood test.
    
    ### What Happens If You Miss a Dose of Ozempic? A Week-Long Half-Life Buys Time
    
    ](https://buythisglp.com/research/what-happens-if-you-miss-a-dose-of-ozempic)
